Ryan White Care Hepatitis C & B Language
NATAP Webinars:
Friday 12:30pm EST - February 13th, 2026
The New Face of Liver Disease in HIV: Viral Hepatitis MASLD, MASH, & HCC
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
Low CD4 Nadir - Impact of Delayed HIV Diagnosis and Treatment on Dementia Risk in Later Life
- (02/06/26)
Examining Survival of People Diagnosed with HIV in Florida Between 2015-2021 Following a Late, Delayed, or Timely Diagnosiss
- (02/02/26)
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA StudyOpen Access
- (01/14/26)
Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects
- (01/14/26)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
- (01/25/26)
AASLD:
HEPATITIS D VIRUS INFECTION PREVALENCE IN PERSONS WITH HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS COINFECTION: A THREE-COUNTRY, CROSS-SECTIONAL STUDY IN EUROPE
- (01/15/26)
AASLD:
TWO DECADES OF HEPATITIS D IN THE UNITED STATES: ESCALATING INCIDENCE, SEX- AND RACE-SPECIFIC PATTERNS, AND NEARLY-DOUBLED RISKS OF CIRRHOSIS AND DECOMPENSATION AMONG ADULTS WITH CHRONIC HEPATITIS B
- (01/15/26)
More Hep D Articles...
Aging & Perinatally Acquired HIV
Modeled Health and Economic Burden of Frailty and Falls Among Adults With HIV
- (01/22/26)
Blood-based Alzheimer's disease biomarkers and cognitive trajectories in older people with HIV with undetectable viral loads
- (01/22/26)
Parkinsonism in people with virally suppressed HIV
- (01/21/26)
Lessons Learned From A Geriatric: co-located in HIV clinic is required
- (01/21/26)
More Aging & HIV Articles...
PrEP
Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
- (01/09/26)
ID Week:
Real-World Persistence to Long-Acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study)
- (11/04/25)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
HCV Testing and Treatment of Adults in the United States: 2014 Through 2021-Data From Two National Commercial Testing Laboratories: 12.8% treated in 2021
- (01/27/26)
Long-term liver stiffness dynamics after sustained virological response in patients with HIV/HCV co-infection and advanced fibrosis
- (01/09/26)
A single-arm phase IIIb study of 8-week glecaprevir/pibrentasvir treatment in adults with acute hepatitis C
- (12/22/25)
AASLD:
Multiscale modeling of results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection
- (11/25/25)
AASLD:
No Impact of RASs on the High Efficacy of BEM and RZR in Combination: Resistance Analysis from a Phase 2 Study in HCV-infected Patients
- (11/25/25)
AASLD:
Bemnifosbuvir and Ruzasvir Provided as a Fixed-Dose Combination Demonstrates High Relative Bioavailability to Their Individual Formulations and Can Be Dosed With No Regard to Food
- (11/25/25)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
AASLD:
Safety, Pharmacokinetics, and Antiviral Activity of the Next-Generation Hepatitis B Capsid Assembly Modulator ABI-4334 in Patients With HBeAg-Negative Chronic Hepatitis B Infection Not Suppressed on Nucleoside Analogues: Results From a Randomized, Blinded, Phase 1b Study
- (12/29/25)
AASLD:
Impact of Baseline HBeAg Status on HBV Outcomes in the ALLIANCE Study
- (11/24/25)
AASLD:
Characterization of HIV/HBV Co-infected Participants Achieving High Rates of Hepatitis B Surface Antigen (HBsAg) Loss in the ALLIANCE Phase 3 Clinical Study
- (11/24/25)
More Hep B Articles...
Fatty Liver, NAFLD, NASH, MASLD, MASH
A Phase 2b, Multicenter, Randomized, Placebo- Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
- (12/29/25)
Reduction of Liver Fibrosis by Al-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2b IMPACT Trial
- (12/29/25)
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
- (12/29/25)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
Conference List Here
https://www.croiconference.org/
https://academicmedicaleducation.com/programs/3rd-african-workshop-on-women-and-hiv-2026
https://academicmedicaleducation.com/programs/16th-international-workshop-on-women-and-hiv-2026
https://acthiv.org/
https://ddw.org/?doing_wp_cron=1768748258.8390960693359375000000
https://www.easlcongress.eu/ https://congress-easl.com/
https://asm.org/events/asm-microbe/home
https://academicmedicaleducation.com/programs/24th-european-meeting-on-hiv-and-hepatitis-2026
https://www.iasociety.org/conferences/aids2026
https://academicmedicaleducation.com/programs?page=2
https://academicmedicaleducation.com/programs/27th-international-workshop-on-clinical-pharmacology-of-hiv-hepatitis-and-other-antiviral-drugs-2026
https://academicmedicaleducation.com/programs/9th-conference-on-liver-disease-in-africa-colda-2026
https://academicmedicaleducation.com/programs/17th-international-workshop-on-aging-and-hiv-2026
https://idweek.org/
https://aasld-igh.org/Home.aspx https://www.aasld.org/the-liver-meeting
https://hivglasgow.org/
